Analysts Set Expectations for CRBU Q1 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities researchers at Brookline Capital Management issued their Q1 2025 earnings estimates for shares of Caribou Biosciences in a research report issued on Tuesday, March 11th. Brookline Capital Management analyst L. Cann forecasts that the company will post earnings of ($0.40) per share for the quarter. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. Brookline Capital Management also issued estimates for Caribou Biosciences’ Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.52) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.15) EPS, FY2026 earnings at ($2.24) EPS, FY2027 earnings at ($3.86) EPS and FY2028 earnings at ($1.74) EPS.

Caribou Biosciences (NASDAQ:CRBU) last posted its earnings results on Monday, March 10th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.01. The company had revenue of $2.08 million for the quarter, compared to analyst estimates of $2.11 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%.

CRBU has been the topic of several other research reports. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Caribou Biosciences in a report on Friday, November 15th. Citigroup lowered their target price on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, November 26th. Finally, Bank of America cut their target price on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $10.33.

Caribou Biosciences Stock Performance

Shares of CRBU stock opened at $1.01 on Thursday. The stock’s 50 day simple moving average is $1.37 and its 200 day simple moving average is $1.78. Caribou Biosciences has a twelve month low of $0.98 and a twelve month high of $5.77. The company has a market capitalization of $91.46 million, a price-to-earnings ratio of -0.61 and a beta of 2.34.

Institutional Trading of Caribou Biosciences

Hedge funds have recently bought and sold shares of the stock. Centric Wealth Management bought a new position in shares of Caribou Biosciences during the 4th quarter worth about $27,000. Erste Asset Management GmbH acquired a new stake in Caribou Biosciences during the third quarter worth about $28,000. Russell Investments Group Ltd. increased its stake in Caribou Biosciences by 859.0% during the fourth quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company’s stock valued at $38,000 after acquiring an additional 21,416 shares during the period. MetLife Investment Management LLC increased its stake in Caribou Biosciences by 60.0% during the fourth quarter. MetLife Investment Management LLC now owns 24,404 shares of the company’s stock valued at $39,000 after acquiring an additional 9,148 shares during the period. Finally, Diametric Capital LP acquired a new position in Caribou Biosciences in the 4th quarter valued at approximately $42,000. 77.51% of the stock is owned by institutional investors.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.